Biogen and Sobi receive positive opinion from CHMP for Elocta(TM) (rFVIIIFc) for the treatment of Haemophilia A
September 25, 2015 07:30 ET
|
Swedish Orphan Biovitrum AB
Biogen (NASDAQ: BIIB) and Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) received a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human...
Swedish Orphan Biovitrum AB (publ) : The board of directors exercises authorisation for repurchase of shares for the purpose of securing the company's commitments under the incentive programme
September 11, 2015 02:30 ET
|
Swedish Orphan Biovitrum AB
The annual general meeting of Swedish Orphan Biovitrum AB (publ) on 30 June 2015 resolved - for the purpose of ensuring that the company can fulfil its commitments under the long-term incentive...
Swedish Orphan Biovitrum AB (publ) : Styrelsen utnyttjar återköpsbemyndigande för säkerställande av bolagets åtaganden enligt incitamentsprogram
September 11, 2015 02:30 ET
|
Swedish Orphan Biovitrum AB
Årsstämman den 30 juni 2015 i Swedish Orphan Biovitrum AB (publ) beslutade - i syfte att säkerställa att bolaget kan fullgöra sina åtaganden enligt det av bolagsstämman beslutade långsiktiga...
Sobi publicerar sin rapport för det andra kvartalet 2015 - höjer utsikterna
July 16, 2015 02:00 ET
|
Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB (publ) (Sobi) presenterade idag sitt resultat för det andra kvartalet 2015. Intäkterna för kvartalet uppgick till totalt SEK 764 M (663), en ökning med 15 procent...
Sobi publishes its Report for the Second Quarter 2015 - raises guidance
July 16, 2015 02:00 ET
|
Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB (publ) (Sobi) today announced its results for the second quarter 2015. Revenues for the quarter totalled SEK 764 M (663), an increase of 15 per cent year-on year. The...
Sobi exercises opt-in right for Alprolix®
July 16, 2015 01:59 ET
|
Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) announced today that the company has decided to exercise its opt-in right to take over final development and commercialisation of Alprolix...
Sobi utnyttjar option på Alprolix®
July 16, 2015 01:59 ET
|
Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) meddelade idag att företaget har beslutat utnyttja sin rättighet att slututveckla och kommersialisera Alprolix (rFIXFc) i Europa, Nordafrika...
Resolutions from Sobi's Annual General Meeting
June 30, 2015 10:15 ET
|
Swedish Orphan Biovitrum AB
The Swedish Orphan Biovitrum AB (publ) (Sobi) Annual General Meeting (AGM) convened earlier today in Stockholm and voted in favour of the resolutions proposed at the meeting, including: Adoption...
Kommuniké från Sobis årsstämma
June 30, 2015 10:15 ET
|
Swedish Orphan Biovitrum AB
Vid Swedish Orphan Biovitrum AB (publ):s (Sobi) årsstämma i Stockholm idag beslutade aktieägarna, i enlighet med föreslagna beslut, följande: Fastställande av resultat- och balansräkningarna samt...
Biogen and Sobi announce European Medicines Agency validates Alprolix® (rFIXFc) marketing authorisation application
June 26, 2015 02:00 ET
|
Swedish Orphan Biovitrum AB
Cambridge, Mass., USA and Stockholm, Sweden, 26 June 2015 Biogen (NASDAQ: BIIB) and Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) today announced that the European Medicines Agency (EMA)...